Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SYNECTICS PLC Director's Dealing 2018

Nov 27, 2018

7942_dirs_2018-11-27_357ec870-c0c9-4132-b579-683926770a6d.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6405I

Synectics PLC

27 November 2018

## 27 November 2018

Synectics plc

(the "Company")

Director / PDMR shareholding

The Company announces that on 26 November 2018 the Trustee of the Company's HMRC Approved Employee Share Acquisition Plan ("ESAP") reinvested the Company's interim dividend and allocated a total of 338 ordinary shares of 20 pence each in the Company to ESAP participants.  The shares were purchased on 26 November 2018 at a price of £1.92 per share.

As a result, the Company has been notified that Paul Webb and Mike Stilwell, directors of the Company, have acquired an interest in 36 shares and 21 shares respectively. Greg Alcorn, divisional director and PDMR of the Company acquired 5 shares.

Name Position Ordinary shares held Interest in shares in  Share Schemes Resultant

Total

Interest
% of

Issued

Share Capital
Paul Webb Chief Executive 36,322 251,920 288,242 1.62
Mike Stilwell Finance Director 6,910 26,294 33,204 0.18
Greg Alcorn Divisional Director 0 11,399 11,399 0.06

For further information, please contact:

Synectics plc Tel: +44 (0) 1527 850 080
Mike Stilwell, Company Secretary [email protected]

www.synecticsplc.com
Stockdale Securities Tel: +44 (0) 20 7601 6100
Tom Griffiths / Henry Willcocks

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHEAFFXAAKPFFF